...
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Implementation of additional prescribing authorization among oncology pharmacists in Alberta
【24h】

Implementation of additional prescribing authorization among oncology pharmacists in Alberta

机译:艾伯塔省肿瘤药学家额外处方授权的实施

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose To describe the practice settings and prescribing practices of oncology pharmacists with additional prescribing authorization. Methods A descriptive, cross-sectional survey of all oncology pharmacists in Alberta was conducted using a web-based questionnaire over four weeks between March and April 2016. Pharmacists were identified from the Cancer Services Pharmacy Directory and leadership staff in Alberta Health Services. Descriptive statistics were used to describe the practice setting, prescribing practices, motivators to apply for additional prescribing authorization, and the facilitators and barriers of prescribing. Logistic regression was used to explore factors associated with having additional prescribing authorization. Results The overall response rate was 41% (71 of 175 pharmacists). Oncology pharmacists with additional prescribing authorization made up 38% of respondents. They primarily worked in urban, tertiary cancer centers, and practiced in ambulatory care. The top 3 clinical activities they participated in were medication reconciliation, medication counseling/education, and ambulatory patient assessment. Respondents thought additional prescribing authorization was most useful for ambulatory patient assessment and follow-up. Antiemetics were prescribed the most often. The median number of prescriptions written in an average week of clinical work was 5. Competence, self-confidence, and the potential impact on patient care/perceived impact on work environment were the strongest facilitators of prescribing. The strongest motivators to apply for additional prescribing authorization were relevancy to practice, the potential for increased efficiency, and advancing the profession. Conclusion The current majority of oncology pharmacist prescribing in Alberta occurs in ambulatory care with a large focus on antiemetic prescribing. Pharmacists found additional prescribing authorization most useful for ambulatory patient assessment and follow-up.
机译:目的,用额外的处方授权来描述肿瘤药学家的实践环境和规定实践。方法采用2016年3月至4月4周的基于网络的问卷对艾伯塔省的所有肿瘤药学家对艾伯塔省的所有肿瘤药学家进行了描述性的横截面调查。药剂师从艾伯塔省卫生服务的癌症服务药房目录和领导人员中核查了药剂师。描述性统计数据用于描述练习设定,处方规定,申请额外处方授权的促进者,以及促进者和处方障碍。 Logistic回归用于探索与具有额外处方授权相关的因素。结果总体响应率为41%(175名药剂师的71人)。具有额外处方授权的肿瘤药学家占受访者的38%。他们主要在城市,第三次癌症中心工作,并在动态护理中实践。他们参与的前3名临床活动是药物和解,药物咨询/教育和外国人患者评估。受访者认为其他规定授权对于行走患者评估和随访最有用。助剂常见于最常进行。在平均一周的临床工作中编写的处长数量为5.竞争力,自信,以及对患者护理/感知对工作环境的影响的潜在影响是处方最强的促进者。申请额外处方授权的最强动机是有关实践的相关性,提高效率的潜力,以及推进专业。结论艾伯塔省目前大多数肿瘤药物在艾伯塔省的药剂师出现在动态护理中,略微关注止吐例。药剂师发现额外的处方授权对于动物患者评估和随访最有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号